Staging System News Today

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.

Press release content from PR Newswire. The AP news staff was not involved in its creation. Ping An AskBob Doctor’s Research on Risk Prediction Approach to Tailor Cancer Treatments Published in International Journal JNCI March 9, 2021 GMT HONG KONG and SHANGHAI, March 9, 2021 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An” or the “Group”, HKEX: 2318; SSE: 601318) is pleased to announce that promising research on the artificial intelligence (AI) te...

ESOU 2021: Surgical and Perioperative Challenges of Large Renal Tumors (UroToday.com) At the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 virtual meeting, Dr. Arnaud Mejean discussed surgical and perioperative challenges of large renal tumors, particularly those with vena cava and lymph node involvement. Dr. Mejean notes that statistics from the SEER database suggest that 19% of patients present with locoregional disease, making this an important area of ma...